Asia
Asia leads in bispecific ADCs
Bispecific antibody drug conjugates represent a new and promising development in targeted cancer therapy. The technology combines the precision of monoclonal antibodies with...
Bioteknik
Kina
Premium
Xintela: »Interest in cell therapy is very high in Asia«
With a busy 2018 in the rearview mirror, Xintela has...